Clinical Trial

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

Suspended Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 20, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Why the trial stopped
Study team is finding new fundings for the study
Summary
This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-24; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Suspended 2026-04-15
Trial Details
NCT Number NCT06894225
Lead Sponsor National Neuroscience Institute
Conditions Recurrent Glioblastoma
Enrollment 12 participants
Start Date 2025-03-22
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-20